Risk factors for opportunistic infections in patients with inflammatory bowel disease

被引:850
作者
Toruner, Murat [1 ]
Loftus, Edward V., Jr. [1 ]
Harmsen, W. Scott [2 ]
Zinsmeister, Alan R. [2 ]
Orenstein, Robert [3 ]
Sandborn, William J. [1 ]
Colombel, Jean-Frederic [4 ]
Egan, Laurence J. [1 ,5 ]
机构
[1] Mayo Clin, Coll Med, Rochester, MN USA
[2] Mayo Clin, Coll Med, Div Biostat, Rochester, MN USA
[3] Univ Coll Hosp Galway, Dept Pharmacol & Therapeut, Div Infect Dis, Galway, Ireland
[4] Ctr Hosp Reg Univ Lille, Dept Gastroenterol Hepatol, Lille, France
[5] Natl Univ Ireland Univ Coll Galway, Dept Pharmacol, Galway, Ireland
关键词
D O I
10.1053/j.gastro.2008.01.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: We sought to identify and quantify the clinical factors that were associated with opportunistic infections in inflammatory bowel disease patients. Methods: We identified 100 consecutive IBD patients with opportunistic infections. For each case, 2 matched IBD patients who did not have a history of opportunistic infection were selected as controls. Conditional logistic regression was used to assess associations between putative risk factors and opportunistic infections, presented as odds ratios (OR) and 95% confidence intervals (CIs). Results: In univariate analysis, use of corticosteroids (OR, 3.4; 95% CI, 1.8-6.2), azathioprine/6-mercaptopurine (OR, 3.1; 95% CI, 1.7-5.5), and infliximab (OR, 4.4; 95% Cl, 1.2-17.1) were associated individually with significantly increased odds for opportunistic infection. Multivariate analysis indicated that use of any one of these drugs yielded an OR of 2.9 (95% CI, 1.5-5.3), whereas use of 2 or 3 of these drugs yielded an OR of 14.5 (95% Cl, 4.9-43) for opportunistic infection. The relative risk of opportunistic infection was greatest in IBD patients seen at older than 50 years of age (OR, 3.0. 95% CI, 1.2-7.2, relative to those 24 years or younger). No patient died from opportunistic infection. Conclusions: Immunosuppressive medications, especially when used in combination, and older age are associated with increased risk of opportunistic infections. The absolute risk of opportunistic infection in IBD patients remains to be determined, as does any potential benefit of any preventive strategy.
引用
收藏
页码:929 / 936
页数:8
相关论文
共 35 条
[1]   Methods to avoid infections in patients with inflammatory bowel disease [J].
Aberra, FN ;
Lichtenstein, GR .
INFLAMMATORY BOWEL DISEASES, 2005, 11 (07) :685-695
[2]   Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients [J].
Aberra, FN ;
Lewis, JD ;
Hass, D ;
Rombeau, JL ;
Osborne, B ;
Lichtenstein, GR .
GASTROENTEROLOGY, 2003, 125 (02) :320-327
[3]  
Ang YS, 2006, GUT, V55, P580
[4]   Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis [J].
Arts, J ;
D'Haens, G ;
Zeegers, M ;
Van Assche, G ;
Hiele, M ;
D'Hoore, A ;
Penninckx, F ;
Vermeire, S ;
Rutgeerts, P .
INFLAMMATORY BOWEL DISEASES, 2004, 10 (02) :73-78
[5]   Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial [J].
Colombel, Jean-Frederic ;
Sandborn, William J. ;
Rutgeerts, Paul ;
Enns, Robert ;
Hanauer, Stephen B. ;
Panaccione, Remo ;
Schreiber, Stefan ;
Byczkowski, Dan ;
Li, Ju ;
Kent, Jeffrey D. ;
Pollack, Paul F. .
GASTROENTEROLOGY, 2007, 132 (01) :52-65
[6]   The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Egan, LJ ;
Harmsen, WS ;
Schleck, CD ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2004, 126 (01) :19-31
[7]   Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Pemberton, JH ;
Wolff, BG ;
Young-Fadok, T ;
Harmsen, WS ;
Schleck, CD ;
Sandborn, WJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (05) :878-883
[8]   Chemotherapy-induced neutropenia - Risks, consequences, and new directions for its management [J].
Crawford, J ;
Dale, DC ;
Lyman, GH .
CANCER, 2004, 100 (02) :228-237
[9]   Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine [J].
Dayharsh, GA ;
Loftus, EV ;
Sandborn, WJ ;
Tremaine, WJ ;
Zinsmeister, AR ;
Witzig, TE ;
Macon, WR ;
Burgart, LJ .
GASTROENTEROLOGY, 2002, 122 (01) :72-77
[10]   Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease [J].
Disanti, William ;
Rajapakse, Ramona O. ;
Korelitz, Burton I. ;
Panagopoulos, Georgia ;
Bratcher, Jason .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (08) :1025-1029